Substance Treatment and HIV Testing and Referral System (STaRS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Polaris Health Directions.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
University of Massachusetts, Worcester
Information provided by (Responsible Party):
Polaris Health Directions
ClinicalTrials.gov Identifier:
NCT01488630
First received: December 1, 2011
Last updated: December 6, 2011
Last verified: December 2011
  Purpose

The lack of substance screening and referral in healthcare settings is a significant problem with far-reaching consequences, including excess morbidity, premature mortality, and inflated healthcare costs. An easy to use, time-efficient referral system is needed to address this problem. The Substance Treatment Referral Systems (STaRS), a computer assisted screening and referral system, was developed to meet this need.

STaRS Phase I demonstrated the feasibility of STaRS to meet this need. All aims and evaluation goals of the Phase I study were met or exceeded. The purpose of the Phase II research is to demonstrate the clinical utility and commercial viability of STaRS.

Specific Aims of Phase II are:

  1. Integrate STaRS with the Epic electronic health record used in the Cooper Health System in Camden, N.J.
  2. Document STaRS' effectiveness in (a) increasing the number of referrals provided for substance abuse treatment and HIV screening, and (b) increasing the proportion of patients that initiate specialty treatment.
  3. Evaluate clinician acceptance and impact upon revenue generation.

The research will be conducted at Cooper Family Medicine (CFM) department of Cooper University Hospital in New Jersey. We will determine the rate of referrals and treatment initiation for 3,500 adult patients treated during treatment as usual (the time before STaRS is implemented at CFM) as well as 3,500 adult patients treated after the introduction of STaRS. Patients will be asked about the referral initiation process, and CFM healthcare providers will be asked to evaluate the system from a clinical and administrative prospective. Finally, billing records will be reviewed during the STaRS implementation to determine whether STaRS impacted revenue for the practices.


Condition Intervention Phase
Substance Abuse
Other: STaRS
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Substance Treatment Referral System

Resource links provided by NLM:


Further study details as provided by Polaris Health Directions:

Primary Outcome Measures:
  • Referral Rates for Substance Abuse Treatment and HIV Testing [ Time Frame: Completed after 3500 pre-STaRS charts and 3500 STaRS intervention charts are reviewed, over a period of one year ] [ Designated as safety issue: No ]
    A total of 7000 electronic health records ( referred to as "charts") will be reviewed for referral rates. Those charts include 3500 pre-STaRS charts (treatment as usual arm) and 3500 STaRS charts (intervention arm)


Secondary Outcome Measures:
  • Treatment Initiation [ Time Frame: 70 pre-STarS patients and 70 STaRS patients are enrolled, over a period of six months ] [ Designated as safety issue: No ]
    7000 charts will be reviewed, 140 patients who received referrals for substance abuse and/or HIV testing will be enrolled in the treatment initiation study (70 with referrals from pre-STaRS charts and 70 with referrals from STaRS intervention charts.

  • Billing Revenue [ Time Frame: 7000 charts reviewed, over a period of one year ] [ Designated as safety issue: No ]
    A total of 7000 electronic health records will be reviewed for referral rates (3500 pre-STaRS, 3500 STaRS intervention). Charts of patients who received referrals will be further examined to obtain billing information. This will help determine the impact that STaRS has on increasing revenues to the CFM practices.

  • Provider Satisfaction [ Time Frame: Last month of the study, November 2012 ] [ Designated as safety issue: No ]
    Focus groups will be conducted with healthcare providers who used the STaRS to make referrals. Data collected at focus groups will be used to improve future versions of STaRS.


Estimated Enrollment: 140
Study Start Date: December 2011
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Treatment as Usual Other: STaRS
The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
Experimental: STaRS Other: STaRS
The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.

Detailed Description:

STaRS is a computer assisted screening and referral system for problem substance use, designed for use in medical settings. The primary function of STaRS is to facilitate physician referrals for tobacco, alcohol, other drugs, and HIV screening, tailored to the patient's condition and circumstances (e.g., zip code and insurance).

A prototype of STaRS was developed and found to be feasible in medical settings in Phase I. Phase II research will demonstrate clinical utility and commercial viability of the system in a medical setting (e.g., Cooper University Hospital Family Medicine practices). Prior to beginning the Phase II research, focus groups were conducted to refine changes to the STaRS software. These focus groups consisted of healthcare providers from Cooper Family Medicine (CFM) practices.

The Phase II research will be conducted in several parts, described in the following sub-studies, conducted simultaneously:

  1. Referral Sub-Study. To determine the impact of STaRS on the rate of referral for substance abuse treatment and HIV screening, 7,000 adult patients' charts will be reviewed (3,500 patients seen prior to STaRs implementation and 3,500 patients seen after STaRS implementation).
  2. Treatment Initiation Sub-Study. To test the effectiveness of STaRS on treatment initiation, 140 patients who receive referrals during the STaRS implementation will be telephoned by research staff and invited to participate in this sub-study to document treatment initiation. Treatment initiation refers to whether the patient has made contact or scheduled an appointment with the referral provider.
  3. Billing and Revenue Generation Sub-Study. Seven thousand medical records will be reviewed for the referral study (described above). Patients who were given referrals for substance use and HIV screening will have their billing records reviewed by the Cooper Research Assistant (RA). The goal is to determine the amount billed for the session in which the referral was made and the amount paid by the insurer (or Medicaid, Medicare). This data will be used to determine the effectiveness of STaRS to increase revenues for the practices.
  4. Provider Evaluation of STaRS Sub-Study. At the conclusion of the study, focus groups will be conducted with the CFM healthcare providers. The focus groups will have 3 goals: Rating the STaRS system on ease of use and clinical utility; soliciting suggestions regarding enhancements to STaRS and procedures to implementation and training; and identifying any factors that may have influenced the providers to screen or refer patients.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All English-speaking adult patients (>= 18 years old) who received a referral for substance abuse treatment or HIV/AIDS screening from Cooper Family Medicine practices during the study period, and who can be reached at a home telephone or have a monthly cell phone plan.

Exclusion Criteria:

  • Patients < 18 years old and patients with poor English comprehension, or who do not have reliable telephone access (i.e., no phone access or buys minutes for a "disposable" cell phone)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01488630

Contacts
Contact: Tina Harralson, PhD 215-359-3892 tharralson@polarishealth.com
Contact: Grant Grissom, PhD 215-359-3912 grant@polarishealth.com

Locations
United States, New Jersey
Cooper Family Medicine Not yet recruiting
Camden, New Jersey, United States, 08102
Principal Investigator: Grant Grissom, PhD         
Sub-Investigator: Edwin D Boudreaux, PhD         
Sponsors and Collaborators
Polaris Health Directions
University of Massachusetts, Worcester
Investigators
Principal Investigator: Grant Grissom, PhD Polaris Health Directions
  More Information

No publications provided

Responsible Party: Polaris Health Directions
ClinicalTrials.gov Identifier: NCT01488630     History of Changes
Other Study ID Numbers: N44DA-10-5543, STaRS
Study First Received: December 1, 2011
Last Updated: December 6, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Polaris Health Directions:
substance abuse
alcohol
drug
smoking
HIV screening

ClinicalTrials.gov processed this record on October 30, 2014